For nearly 25 years, James Kyle Bryan, M.D. has excelled in his career as a hematologist and oncologist. He now brings that experience, along with more than 20 years of drug development expertise with both pharmaceutical companies and global CROs, to Novella Clinical. As Chief Medical Officer he provides medical and scientific leadership for Novella’s Medical and Safety Management teams and consulting services to sponsors regarding preclinical and clinical data, regulatory strategy, protocol design and drug development strategy. His guidance and expertise help ensure the safety of patients during clinical trials conducted by Novella.
Prior to joining Novella Clinical, Dr. Bryan served as chief medical officer for VentiRx Pharmaceuticals in Seattle, where he was responsible for moving immuno-oncology compounds into and through the clinical development process, including trial design and execution, clinical research, and data analysis. He has also served as vice president of medical affairs for Seattle Genetics, managing a national medical affairs team in coordination with clinical development and research groups. In this role he was responsible for overseeing the medical science liaison force, as well as directing the investigator-sponsored study and expanded access program, publication strategy, and medical information. Other previous roles include vice president of global drug development at a global CRO, and director of clinical research at NeoRx Corporation.
Dr. Bryan remains active clinically, holding an appointment as a clinical instructor for hematology and oncology at the University of Washington Medical Center and Harborview Medical Center. He was previously head of the division of hematology and oncology at Pacific Medical Center, where he was an investigator on institutional and cooperative group trials, and helped develop institutional guidelines and medical training programs. He has developed evaluation and management algorithms for diseases including anemia, leukopenia, thrombocytopenia, bleeding, hypercoagulability, and others.
A distinguished writer, Dr. Bryan has co-authored more than 20 peer reviewed publications, including articles published in Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, and Clinical Cancer Research.
Dr. Bryan is an alumnus of Louisiana State University, where he received both his bachelor’s degree in biochemistry as well as his medical degree, and served as clinical chief resident. He completed his fellowship in hematology and oncology at the University of Washington, and is board certified in medical oncology and hematology.
With clinical trial expertise stemming both from his time as a clinician and his experience in pharmaceuticals, Dr. Bryan brings a unique understanding of oncology research that benefits Novella and our customers.